A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD).

The effectiveness of XEN-D0501 placebo in reducing capsaicin cough responses, objective 24-hour cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale [VAS]), urge to cough (via VAS), global rating of change scale, Clinical COPD Questionnaire (CCQ), Leicester Cough Questionnaire (LCQ), and St George's Respiratory Questionnaire (SGRQ-C) will be evaluated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xention Ltd
• Collaborator: Ario Pharma Ltd

Criteria

Inclusion Criteria:

• Male/female subjects aged 40 or over with COPD

Exclusion Criteria:

• Clinically significant medical history

• Abnormal laboratory results, ECGs or vital signs